VYXEOS was developed to persist in the bone marrow, leading to prolonged and controlled levels of daunorubicin and cytarabine that reach leukemia cells.1,23,a
aBased on animal studies; clinical relevance unknown.
VYXEOS liposomes penetrate and persist in the bone marrow.1,a
aBased on animal studies; clinical relevance unknown.
The synergistic 1:5 molar ratio of daunorubicin and cytarabine has demonstrated increased activity vs free drug in vitro and in murine models, thereby enhancing the killing of leukemia cells.1,23,a
aBased on animal studies; clinical relevance unknown.
VYXEOS is released into the intracellular environment and has a longer half-life than traditional daunorubicin and cytarabine, which results in greater drug exposure within the plasma and bone marrow than traditional chemotherapy.1,24,a
aBased on animal studies; clinical relevance unknown.
